U.S., Aug. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07743827) titled 'Olanzapine Based Dexamethasone-sparing Regimen for Breast Cancer Patients With Metabolic-risk Factors' on July 27.
Brief Summary: The aim of THE STUDY to determine whether an olanzapine-based dexamethasone-sparing antiemetic regimen is non-inferior to the standard dexamethasone-containing regimen in preventing delayed-phase Chemotherapy-induced nausea and vomiting while reducing metabolic toxicity in breast cancer patients with metabolic risk factors.
Study Start Date: May 10
Study Type: INTERVENTIONAL
Condition:
Olanzapine
Breast Cancer
Dexamethasone
Intervention:
DRUG: Pantoprazole
Administered as 40 mg orally once daily on ...